{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2017"],"condition":["Colorectale kanker","Colorectal cancer"],"disease":["Colorectal Cancer","Colorectale Kanker"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2536570"],"location":["Belgium"],"study_start_month":["5"],"keyword":["CELEBREX 200 mg harde capsules"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"The influence of the human body on the fate of Celebrex for the prevention/treatment of colorectal cancer: plasma concentration and elimination of Celebrex in healthy volunteers","description":"Primary objectives: To study the pharmacokinetics of Celecoxib for the prevention/treatment of colorectal cancer\nPrimary endpoints: The pharmacokinetic profiling of Celecoxib following oral administration in healthy volunteers","dates":{"creation":"2017-05-15"},"accession":"2536570","cross_references":{"EU Clinical Trials Register":["2017-000131-13"]}}